Rapid Therapeutic Science Laboratories, Inc. (RTSL) Debt to Equity (2016 - 2023)
Rapid Therapeutic Science Laboratories' Debt to Equity history spans 8 years, with the latest figure at -$0.02 for Q2 2023.
- For Q2 2023, Debt to Equity rose 94.62% year-over-year to -$0.02; the TTM value through Jun 2023 reached -$0.02, up 94.62%, while the annual FY2022 figure was -$0.01, N/A changed from the prior year.
- Debt to Equity for Q2 2023 was -$0.02 at Rapid Therapeutic Science Laboratories, up from -$0.05 in the prior quarter.
- Across five years, Debt to Equity topped out at -$0.01 in Q4 2022 and bottomed at -$6.87 in Q3 2021.
- The 5-year median for Debt to Equity is -$0.23 (2019), against an average of -$1.05.
- The largest annual shift saw Debt to Equity plummeted 597.57% in 2020 before it surged 99.72% in 2022.
- A 5-year view of Debt to Equity shows it stood at -$0.55 in 2019, then tumbled by 597.57% to -$3.87 in 2020, then crashed by 77.56% to -$6.87 in 2021, then surged by 99.81% to -$0.01 in 2022, then crashed by 51.15% to -$0.02 in 2023.
- Per Business Quant, the three most recent readings for RTSL's Debt to Equity are -$0.02 (Q2 2023), -$0.05 (Q1 2023), and -$0.01 (Q4 2022).